Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Blog

Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.

Page 10

Trial readouts

Semaglutide for Young People

An English expert consensus follows STEP TEENS, where semaglutide reduced adolescent BMI but adverse events and policy limits still matter.

5 Nov 2026 · PeptideMethods Editorial Team · 5 min read
Country deep-dive

Retatrutide import rules in Denmark

Denmark permits some personal medicine imports, but grey-market retatrutide lacks a verified lawful-sale route under the 2026 rules.

4 Nov 2026 · PeptideMethods Editorial Team · 7 min read
Country deep-dive

Semaglutide status in Denmark

Authorised semaglutide products remain prescription medicines in Denmark. The 2026 change concerns private imports, not deregulation.

4 Nov 2026 · PeptideMethods Editorial Team · 6 min read
Country deep-dive

TB-500 import rules in Denmark

Denmark's 2026 private-import rules are conditional, and TB-500 has no routine authorised Danish pack. Here is the source-bounded answer.

4 Nov 2026 · PeptideMethods Editorial Team · 6 min read
Country deep-dive

TB-500 cost in Denmark

No official Danish TB-500 pharmacy price or routine reimbursement could be verified because no authorised pack was identified.

4 Nov 2026 · PeptideMethods Editorial Team · 6 min read
Country deep-dive

TB-500 status in Denmark

Denmark has no verified authorised TB-500 medicine route. The 2026 import reform did not create an approval or pharmacy product.

4 Nov 2026 · PeptideMethods Editorial Team · 6 min read
Country deep-dive

Tirzepatide import rules in Denmark

Denmark permits some personal tirzepatide imports, but only when the exact medicine was lawfully sold and is supported by proper records.

4 Nov 2026 · PeptideMethods Editorial Team · 8 min read
Trial readouts

Digital Support With GLP-1 Drugs

A retrospective program study linked app use with higher odds of weight-loss milestones, but self-selection prevents a causal conclusion.

4 Nov 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

Semaglutide Safety by Frailty in SELECT

A SELECT post hoc analysis found no detectable difference in cardiovascular benefit across baseline frailty categories, with important safety limits.

4 Nov 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

GLP-1 Injection-Site Amyloidosis Case

A 2026 case report describes a rare abdominal amyloid deposit after use of three injectable incretin medicines, with liraglutide detected at low levels.

3 Nov 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

GLP-1 versus SGLT2: a confounded cohort

A matched records study favored GLP-1 drugs in MASLD with heart failure, but early separation makes treatment channeling likely.

3 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Semaglutide and cardiovascular death

Seven randomized trials suggest a 17% lower relative hazard of cardiovascular death with semaglutide versus placebo.

3 Nov 2026 · PeptideMethods Editorial Team · 4 min read